Table of Content

1. Introduction
1.1. Product Definition
1.2. Research Process
1.3. Assumptions
1.4. Market Segmentation

2. Preface

3. Executive Summary

4. Impact of COVID-19 on China Colorectal Cancer Market

5. China Colorectal Cancer Market Outlook, 2016-2026F
5.1. Market Size & Analysis
5.1.1. Market Revenues
5.2. Market Share & Analysis
5.2.1. By Solution
5.2.1.1. Therapeutics
5.2.1.1.1. Surgery and Radiation Therapy
5.2.1.1.2. Chemotherapy
5.2.1.1.2.1. Alkylating agent
5.2.1.1.2.2. Antimetabolites
5.2.1.1.2.2.1. Fluorouracil
5.2.1.1.2.2.2. Capecitabine
5.2.1.1.2.3. Others
5.2.1.1.3. Targeted Therapies
5.2.1.1.4. Immunotherapy Drugs
5.2.1.1.4.1. Monoclonal antibodies
5.2.1.1.4.1.1. Bevacizumab
5.2.1.1.4.1.2. Cetuximab
5.2.1.1.4.1.3. Panitumumab
5.2.1.1.4.2. Biologic Response Modifiers
5.2.1.1.4.3. Colony-Stimulating Factors
5.2.1.1.4.4. Tumor Vaccines
5.2.1.2. Diagnosis
5.2.1.2.1. Digital Rectal Examination
5.2.1.2.2. Fecal Occult Blood Test
5.2.1.2.3. Flexible Sigmoidoscopy
5.2.1.2.4. Colonoscopy
5.2.1.2.5. Virtual Colonoscopy
5.2.1.2.6. Double Contrast Barium Enema
5.2.2. By Region
5.2.2.1. North
5.2.2.2. North-East
5.2.2.3. North-West
5.2.2.4. East
5.2.2.5. South-West
5.2.2.6. South Central
5.2.3. By Competitors
5.2.3.1. Competition Characteristics
5.2.3.2. Market Share & Analysis
5.2.3.3. Competitive Metrix

6. China Colorectal Cancer Patent Analysis

7. China Colorectal Cancer Government Regulations and Policies

8. China Colorectal Cancer Market Trends & Insights

9. China Colorectal Cancer Market Dynamics
9.1. Growth Drivers
9.2. Challenges
9.3. Impact Analysis

10. China Colorectal Cancer Market Hotspot & Opportunities

11. China Colorectal Cancer Market Key Strategic Imperatives for Success & Growth

12. Competition Outlook
12.1. Competition Matrix
12.1.1. Research & Development
12.1.2. Collaborations & Strategic Alliances
12.1.3. Key Business Expansion Initiatives
12.1.4. Business Restructuring- Mergers, Acquisitions, JVs
12.1.5. Strategic Initiatives
12.2. Company Profiles (Business Description, Product Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
12.2.1. Amgen China
12.2.2. Bristol-Myers Squibb
12.2.3. Bayer AG
12.2.4. Merck KGaA
12.2.5. Roche (china) Co., Ltd.
12.2.6. Eli Lilly and Company
12.2.7. Sanofi China
12.2.8. Taiho Pharmaceutical
12.2.9. Novartis AG
12.2.10. Pfizer Inc.

13. Disclaimer